Article Text

Download PDFPDF

CASE REPORT
Long-term stabilisation of myeloma with curcumin
  1. Abbas Zaidi1,
  2. Maggie Lai2,
  3. Jamie Cavenagh1
  1. 1Department of Haematology, Barts Health NHS Trust, London, UK
  2. 2Myeloma UK, Edinburgh, UK
  1. Correspondence to Dr Abbas Zaidi, abbashmzaidi{at}gmail.com

Summary

Myeloma is a haematological malignancy which typically follows a relapsing-remitting course. While treatment can control the myeloma and improve quality of life for given periods of time, remissions generally become progressively shorter with subsequent relapses, and patients ultimately enter a final refractory phase. To help control symptoms and enhance quality of life, some patients use complementary therapies as an adjunct to their conventional therapy. Here, we describe a myeloma patient who started a daily dietary supplement of curcumin when approaching her third relapse. In the absence of further antimyeloma treatment, the patient plateaued and has remained stable for the last 5 years with good quality of life.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Twitter Follow Maggie Lai @MyelomaUK

  • Contributors AZ and JC involved in treating the described patient initially discussed and planned writing this case. The planning was made with ML of Myeloma UK. Each performed a review of the literature and a summary of the case was provided by AZ and JC to ML who wrote the initial draft. The final paper was edited by AZ and reviewed and edited by JC.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.